MCRB Seres Therapeutics Inc.

15.02
-0.14  -1%
Previous Close 15.16
Open 15.16
Price To book 6.92
Market Cap 608499838
Shares 40,512,639
Volume 101,695
Short Ratio 20.74
Av. Daily Volume 171,492

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171005195
  2. 8-K - Current report 171002782
  3. 8-K - Current report 17956328
  4. 8-K - Current report 17923299
  5. 8-K - Current report 17904582

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b initiated July 2016. Data due early 2018.
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 3 trial initiation announced June 12, 2017.
SER-109 - ECOSPOR III
Recurrent C. Difficile infection
Phase 1b initiated December 2015. Completion of enrollment noted June 5, 2017. Data due 2H 2017
SER-287
Mild-to-Moderate Ulcerative Colitis

Latest News

  1. Seres Therapeutics to Present at the Baird 2017 Global Healthcare Conference
  2. Edited Transcript of MCRB earnings conference call or presentation 3-Aug-17 12:00pm GMT
  3. Seres Therapeutics reports 2Q loss
  4. Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress
  5. Investor Network: Seres Therapeutics Inc to Host Earnings Call
  6. Seres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
  7. Seres Therapeutics to Host Second Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2017
  8. Seres Therapeutics (MCRB) Catches Eye: Stock Gains 9.2%
  9. Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer
  10. Seres Therapeutics' Stock Up as SER-109 Moves to Phase III
  11. Seres Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MCRB-US : June 13, 2017
  12. Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection
  13. Seres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference
  14. ETFs with exposure to Seres Therapeutics, Inc. : June 5, 2017
  15. Seres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis
  16. Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
  17. Edited Transcript of MCRB earnings conference call or presentation 4-May-17 12:00pm GMT
  18. Seres Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MCRB-US : May 5, 2017
  19. Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171005195
  2. 8-K - Current report 171002782
  3. 8-K - Current report 17956328
  4. 8-K - Current report 17923299
  5. 8-K - Current report 17904582
  6. 8-K - Current report 17903059
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814248
  8. 8-K - Current report 17811787
  9. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17801208
  10. DEF 14A - Other definitive proxy statements 17800895